依普利酮作用功能

Eplerenone (Planep) was developed by Pfizer/Pharmacia with the trade name Inspra. It is a new generation of selective aldosterone antagonist. The indications of eplerenone (Planep) include: 1. Congestive heart failure after acute myocardial infarction: Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction; 2. Anti-hypertension: Eplerenone can be used alone or in combination with other anti-hypertensive drugs for the treatment of hypertension.

Effect of eplerenone (Planep): For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant.

Eplerenone (Planep) is used for congestive heart failure after acute myocardial infarction: the recommended dose is 50 mg/time, once/day. The initial dose should be 25 mg/time, once/day, and within 4 weeks, the dose should be gradually increased to 50 mg/time, once/day if the patient tolerates it.

The FDA has approved eplerenone (Inspra - Pfizer) for use in stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and congestive heart failure after acute myocardial infarction (MI) to improve survival. Eplerenone is the first aldosterone receptor blocker approved for this indication. The FDA's approval was based on the results of the EPHESUS (Eplerenone Efficacy and Survival Study in Heart Failure After Acute Myocardial Infarction) trial. In patients with heart failure after myocardial infarction, eplerenone plus standard care reduced mortality by 15% compared with placebo and standard care (ACE inhibitors and beta-blockers). EPHESUS was published in the April 2003 issue of the New England Journal of Medicine.